Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Pancreatic Neoplasms 3Ovarian Neoplasms 2Insulin-Like Growth Factor I, Resistance To 2Colorectal Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × ganitumab × Clear all
NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Novartis

Phase 1/2 Terminated
47 enrolled 23 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡